Latest / AI Investment Edge: Stocks, Markets & Money

EP 36 | GSK Stock Analysis: Can New Drugs Beat the Patent Cliff?
GSK’s patent relay: can current medicines fund their replacements? London ordinary GSK.LSE/GBX; ISIN GB00BN7SWP63. Dated 30 October close: 1,855p (£18.55), not a live Sunday quote.
GSK research · AI Opinions · Fundamentals · Rankings / Strongest Buys
Q3 sales £8.89bn grew 4% AER/5% CER; Total EPS 38.50p fell 23% AER, while Core EPS 54.60p fell 1% AER/rose 1% CER. Core margin 34.60% was nearly flat as R&D rose. Specified adjusting items explain the Total/Core EPS gap; normal research and financing costs affect both measures. September net debt £20.74bn versus £14.45bn in December reflects…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.